Brolucizumab
- Generic Name
- Brolucizumab
- Brand Names
- Beovu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1531589-13-5
- Unique Ingredient Identifier
- XSZ53G39H5
- Background
Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Brolucizumab was granted FDA approval in October 2019.
- Indication
Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath